Cagrilintide for renal insufficiency, chronic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Nov 2023: Trial registered, NCT06131372
  2. 1 Apr 2024: Trial started, NCT06131372

The trials

NCT06131372: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

State
Completed
Phase
Phase 2
People
626 taking part
Started
1 Apr 2024
Primary completion
24 Sep 2025
Arms
Cagrilintide
Results
None posted
  1. 14 Nov 2023: Trial registered
  2. 1 Apr 2024: Trial started
  3. 6 Nov 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.